Audit 322445

FY End
2023-12-31
Total Expended
$247.64M
Findings
0
Programs
111
Year: 2023 Accepted: 2024-09-30

Organization Exclusion Status:

Checking exclusion status...

Findings

No findings recorded

Programs

ALN Program Spent Major Findings
97.036 Covid-19 - Federal Emergency Management Agency Disaster Relief Fund $104.77M Yes 0
93.498 Covid-19 - Provider Relief Fund and American Rescue Plan (arp) Rural Distribution $44.28M Yes 0
84.268 Federal Direct Student Loans-Hackensack Meridian School of Medicine $25.18M - 0
93.855 Covid-19 - Metropolitan Antiviral Drug Accelerator $18.74M - 0
93.855 Center to Develop Therapeutic Countermeasures to High-Threat Bacterial Agents $7.77M - 0
21.027 Covid-19 - Coronavirus State Fiscal Recovery Fund $6.77M Yes 0
84.268 Federal Direct Student Loans $3.34M - 0
84.181 Services: Early Intervention System, Special Education Grants for Infants and Families $2.79M Yes 0
93.323 Covid-19 - Sars-Cov-2 Hospital Testing 2021 $2.76M - 0
93.378 Integrated Care for Kids Model $2.26M - 0
93.855 Harnessing B Cells for Tb Vaccine Development to Improve Therapy of Tb and Tb-Hiv Coinfection $1.46M - 0
93.855 Novel Bi-Specific Immunotherapeutic Against High-Threat Gram-Negative Pathogens $1.12M - 0
21.027 Covid-19 - Arp Hospital Based Violence Intervention Program $995,137 Yes 0
93.493 Community Project Funding/congressionally Directed Spending ‐ Construction $875,704 - 0
84.425 Covid-19 - Higher Education Emergency Relief Fund (heerf) Student Aid $830,276 - 0
93.855 Translational Approaches to Improve Understanding and Outcome in Tuberculous Meningitis $822,603 - 0
93.393 Leveraging Social Media to Increase Lung Cancer Screening Awareness, Knowledge $800,328 - 0
84.425 Covid-19 - Heerf Institutional Aid $800,020 - 0
93.855 Immunometabolic Regulations of Pulmonary Tb Pathogenesis by Adipose Tissue $795,998 - 0
93.855 A Dual-Beta-Lactam Strategy for Treating Multidrug Resistant M Abscessus $772,924 - 0
84.063 Federal Pell Grant Program $762,510 - 0
93.855 Hx Nih Ctcf in Cd8 Tcell $741,842 - 0
93.396 Harnessing the Thymus for Long-Term Tumor Control with Hematopoietic Stem Cell-Derived Naïve Car T Cells $707,909 - 0
93.839 Dot1l, Reconstitution of Plasmacytoid Dendritic Cells and Alloimmunity $663,140 - 0
93.855 Critical Factors Influencing Echinocandin Resistance in Candida Glabrata $651,312 - 0
93.855 Combatting Natural Resistance and Persistence in Non-Tb Mycobacterial Disease $617,205 - 0
93.247 Ane- Nurse Practitioner Residency Program $543,163 - 0
93.396 Study of the Il-33-Driven Immune Cell Organization Underpinning Responses to Immune Checkpoint Blockade Cancer Therapy $519,261 - 0
93.855 Determinants of Tb Control, Relapse and Reinfection $506,234 - 0
93.855 Tcf1 Programs Cd8 T Cell Responses to Enhance Viral and Cancer Immunity $481,230 - 0
93.243 Icare Integrated Care for Addiction Recovery Expansion $480,423 - 0
93.855 Transmission Aerobiology of M. Tuberculosis: Genes and Metabolic Pathways That Sustain Mtb Across An Evolutionary Bottleneck $477,764 - 0
93.395 Study of Interleukin 33 As A New Immunotherapy of Lung Cancer $434,972 - 0
93.855 Synthetic Rescue of Antigen-Driven T Cells and Alloimmunity $408,784 - 0
93.396 Identifying and Characterizing Functional Noncoding Mutations in Multiple Myeloma $408,431 - 0
93.855 Novel Bi-Specific Immunoprophylactics Against Multi-Drug Resistant Gram-Negative Bacterial Infections $405,286 - 0
93.838 Clock (collaborative Long-Term Study of Outcomes of Covid-19 in Kids) Consortium for Pasc Phase II Recover Pediatric Cohort $387,392 - 0
93.855 Antibacterial Resistance Leadership Group (arlg) $367,718 - 0
93.855 Optimization of Rifamycins to Overcome Intrinsic Resistance of Nontuberculous Mycobacteria to Improve Treatment of Ntm Lung Disease $364,512 - 0
21.027 Covid-19 - Coronavirus State Fiscal Recovery Fund Project 2024 $340,263 Yes 0
93.855 Target Based Discovery of Next Generation Pyrazinamide $326,738 - 0
93.865 Epigenetics of Down Syndrome $301,469 - 0
93.398 Experimental Evolution of Pancreatic Cancer $279,489 - 0
93.398 Elucidating the Role of Smad4 in Colorectal Cancer $267,803 - 0
93.914 Hiv Emergency Relief Project Grants $266,272 - 0
93.855 Elucidating Mediators of Genetic Instability in Candida Glabrata $261,153 - 0
93.310 Enriching Echo Cohorts with High-Risk Pregnancies and Children with Disabilities (enriching Echo) $247,678 - 0
93.855 Lesion Pharmacokinetics and Pharmacodynamics to Design New Drugs and Drug Combinations for Tuberculosis $246,846 - 0
93.855 Identifying Drug-Resistant Candida Species Using Superselective Primer Pcr $244,175 - 0
93.917 Hiv/aids Ryan White Part B Application 2023 $244,061 - 0
93.398 Leveraging Behavioral Science to Improve Patient Understanding of Advanced Cancer $238,575 - 0
93.855 C5a/c5ar1 Signaling in Protective Immunity During Invasive Candidiasis $226,564 - 0
93.433 Nidilrr Disability and Rehab. Research Projects Tbi Model Systems $216,543 - 0
93.393 Using A Mixed Methods Approach to Understand Shared Decision-Making in Lung Cancer Screening $215,562 - 0
12.420 Role of Core-Binding Factor Rearrangements in Triple-Negative Breast Cancer Progression and Immune Evasion $211,956 - 0
12.420 Mechanisms of Impaired Swallowing, Speech, and Voice in Parkinson's Disease $206,335 - 0
93.855 Ezh2 Regulates Follicular Helper T Cell Differentiation $203,659 - 0
12.420 Biomarkers and Pathogenesis of Cutaneous Fibrosis $186,411 - 0
93.847 Leptin Reduction As A Potent Mitigative Strategy for the Treatment of Pasc $179,082 - 0
93.855 Novel Strategies for Antibiotic Combinations to Combat Gram-Negative Superbugs $169,166 - 0
12.420 Reinnervation of Paralyzed Limb Muscle by Nerve-Muscle-Endplate Grafting Technique $167,243 - 0
93.855 Targeting Biotin Metabolism in Mycobacterium Tuberculosis $158,357 - 0
93.273 Peptide Therapy for Alcohol-Induced Cns Injury $157,552 - 0
93.243 Hmh Carrier Clinic Mental Health Awareness in Identifying Disturbances in Emotions Program (aide) $140,192 - 0
93.924 Ryan White Hiv/aids Dental Reimbursements $133,135 - 0
93.397 Epigenetic Therapies - New Approaches, Project 1 $127,144 - 0
93.870 New Jersey Home Visiting Initiative: Parents As Teachers $117,975 - 0
93.393 Tmem, Menacalc, and Menainv As Prognostic and Predictive Markers for Breast Cancer Metastasis $113,129 - 0
16.575 Community-Based Violence Intervention Program $107,289 - 0
12.420 Pinpointing Functional Noncoding Mutations in Ccrcc $100,728 - 0
93.855 Antibiotic Resistance Among Hypermutator Carbapenem Resistant Klebsiella Pneumoniae $87,797 - 0
93.153 Pediatric Aids 2023 $84,470 - 0
93.855 A Preclinical Program for Targeting Mycobacterium Tuberculosis Kasa $83,780 - 0
84.007 Federal Supplemental Education Opportunity Grant Program $82,800 - 0
93.917 Hiv/aids Ryan White Part B Application 2022 $77,268 - 0
93.393 Bridging Information Divides and Gaps to Ensure Survivorship $69,051 - 0
93.226 Simulation to Improve Infection Prevention and Patient Safety: the Sipps Trial $67,925 - 0
93.855 Bacterial Characteristics of Community-Associated Carbepenem-Resistant Enterobacteriaceae $67,793 - 0
93.153 Pediatric Aids 2024 $62,976 - 0
93.310 Development Impact of Nicu Exposures (dine) $62,680 - 0
93.393 Population-Based Assessment of Patient-Reported Outcomes in Adults Living with Metastatic Colorectal Cancer $57,434 - 0
93.855 Serine/threonine Kinase Signaling in Beta-Lactam Resistance of Staphylococcus Aureus $52,643 - 0
93.853 Comparing Treatment Approaches to Promote Inpatient Rehabilitation Effectiveness for Traumatic Brain Injury (care 4 Tbi) $49,739 - 0
93.433 Characterization and Treatment of Chronic Pain After Severe Traumatic Brain Injury $44,700 - 0
93.865 The Patient Journey for Children with Medical Complexity During the Pandemic Era and Its Implications $44,467 - 0
16.045 Project Heal: Expansion of Community-Based Violence Intervention & Prevention Initiatives $38,230 - 0
93.994 Healthy Women Healthy Families 2024 $36,441 - 0
93.866 Rejuvenation of Aged Hematopoietic Stem Cells and Endothelial Niches by Thrombospondin-1 Blocade $36,025 - 0
93.855 Modulating Costimulation Pathways to Improve Follicular Helper T Cell and Antibody Responses $32,088 - 0
93.914 Ryan White $31,024 - 0
93.393 Multilevel Interventions to Increase Adherence to Lung Cancer Screening $30,867 - 0
93.398 Optimizing Adherence to Lung Cancer Screening: Applying Theory and Implementation Science to Participant Engagement $30,328 - 0
93.940 Ending the Epidemic: to Perform Enhanced Hiv Services $30,000 - 0
93.243 Expanded Interprofessional Medication-Assisted Treatment Training Program $29,998 - 0
93.994 Special Child Health Child Evaluation Centers 2024 $27,975 - 0
93.994 Special Child Health Child Evaluation Centers 2023 $26,835 - 0
93.866 Escitalopram in Agitation in Alzheimer Disease $25,626 - 0
93.393 Empathic Communication Skills Training to Reduce Lung Cancer Stigma $23,297 - 0
93.855 Synthesizability-Constrained Expansion and Multi-Objective Evolution of Antitubercular Compounds $21,661 - 0
93.397 Epigenetic Therapies - New Approaches, Pathology Core $21,431 - 0
93.394 Nourish-T+: A Randomized Control Trial Targeting Parents $16,333 - 0
93.590 Community Prevention Direct Service $15,323 - 0
93.853 Targeting Lewy Body Specific Pathology Using Biomarkers $15,049 - 0
93.855 Defining Stim1 Function at the Immunological Synapse $14,841 - 0
93.110 Pediatric Mental Health Care Access Program $14,235 - 0
93.855 Novel Dual-Stage Antimalarials: MacHine Learning Prediction, Validation and Evolution $10,116 - 0
93.395 Lncrna Epic1 Induces Immunotherapy Resistance by Activating Ezh2 in Breast Cancer $9,038 - 0
93.397 Fit & Quit 2.0: Feasibility and Usability Testing $5,873 - 0
93.395 Role of Lsd1 in Triple Negative Breast Cancer Development and Therapeutic Response $5,430 - 0
93.866 Telerehabilitation Combining Virtual Reality Adaptable Games and Drug Therapy for Early Alzheimer’s Disease $5,155 - 0
93.855 Siderophore Inhibitors for Tuberculosis That Block Mycobactin Biosynthesis $2,344 - 0

Contacts

Name Title Type
LV8GL8MLU9A3 Carrie Simeone Auditee
9086757265 Timothy Weld Auditor
No contacts on file

Notes to SEFA

Title: Basis of Presentation Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the “Federal Schedule”) presents the activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. and its subsidiaries (the "Network") that have been financed by the U.S. Government. The information in this Federal Schedule is presented in accordance with the requirements of the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this Federal Schedule may differ from amounts presented in or used in preparation of the consolidated financial statements. All financial assistance received directly from federal agencies, as well as financial assistance passed through other governmental agencies or nonprofit organizations, are included on the Federal Schedule. Direct and indirect costs are charged to awards in accordance with cost principles contained in the Uniform Guidance, U.S. Office of the Assistant Secretary Comptroller ("OASC"), OASC-3, A Guide for Hopsitals. Under these cost principles, certain types of expenditures are not allowable or are limited as to reimbursement. The accompanying Federal Schedule is presented on the accrual basis of accounting. Because the Federal Schedule presents only a selected portion of the activities of the Network, it is not intended to, and does not, present the consolidated financial position, results of operations, and changes in net assets or cash flows of the Network. While certain awards on the Federal Schedule have program names identified as award year 2021, 2022 and 2024 only expenses incurred during the year ended December 31, 2023 are reported on the Federal Schedule. These awards have grant periods that do not align with the Network's calendar year end. De Minimis Rate Used: N Rate Explanation: The Network charges indirect costs to federal awards based on award-specific rates as defined in each grant award. The accompanying Schedule of Expenditures of Federal Awards (the “Federal Schedule”) presents the activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. and its subsidiaries (the "Network") that have been financed by the U.S. Government. The information in this Federal Schedule is presented in accordance with the requirements of the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this Federal Schedule may differ from amounts presented in or used in preparation of the consolidated financial statements. All financial assistance received directly from federal agencies, as well as financial assistance passed through other governmental agencies or nonprofit organizations, are included on the Federal Schedule. Direct and indirect costs are charged to awards in accordance with cost principles contained in the Uniform Guidance, U.S. Office of the Assistant Secretary Comptroller ("OASC"), OASC-3, A Guide for Hopsitals. Under these cost principles, certain types of expenditures are not allowable or are limited as to reimbursement. The accompanying Federal Schedule is presented on the accrual basis of accounting. Because the Federal Schedule presents only a selected portion of the activities of the Network, it is not intended to, and does not, present the consolidated financial position, results of operations, and changes in net assets or cash flows of the Network. The Network does not use the 10% de-minimis indirect cost rate for sponsored programs. The Network charges indirect costs to federal awards based on award-specific rates as defined in each grant award. While certain awards on the Federal Schedule have program names identified as award year 2021, 2022 and 2024 only expenses incurred during the year ended December 31, 2023 are reported on the Federal Schedule. These awards have grant periods that do not align with the Network's calendar year end.
Title: Pass-through Awards Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the “Federal Schedule”) presents the activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. and its subsidiaries (the "Network") that have been financed by the U.S. Government. The information in this Federal Schedule is presented in accordance with the requirements of the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this Federal Schedule may differ from amounts presented in or used in preparation of the consolidated financial statements. All financial assistance received directly from federal agencies, as well as financial assistance passed through other governmental agencies or nonprofit organizations, are included on the Federal Schedule. Direct and indirect costs are charged to awards in accordance with cost principles contained in the Uniform Guidance, U.S. Office of the Assistant Secretary Comptroller ("OASC"), OASC-3, A Guide for Hopsitals. Under these cost principles, certain types of expenditures are not allowable or are limited as to reimbursement. The accompanying Federal Schedule is presented on the accrual basis of accounting. Because the Federal Schedule presents only a selected portion of the activities of the Network, it is not intended to, and does not, present the consolidated financial position, results of operations, and changes in net assets or cash flows of the Network. While certain awards on the Federal Schedule have program names identified as award year 2021, 2022 and 2024 only expenses incurred during the year ended December 31, 2023 are reported on the Federal Schedule. These awards have grant periods that do not align with the Network's calendar year end. De Minimis Rate Used: N Rate Explanation: The Network charges indirect costs to federal awards based on award-specific rates as defined in each grant award. Full Assistance Listing Numbers (“ALN”) and pass-through award numbers are presented where available and applicable
Title: Federal Direct Student Loan Program Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the “Federal Schedule”) presents the activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. and its subsidiaries (the "Network") that have been financed by the U.S. Government. The information in this Federal Schedule is presented in accordance with the requirements of the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this Federal Schedule may differ from amounts presented in or used in preparation of the consolidated financial statements. All financial assistance received directly from federal agencies, as well as financial assistance passed through other governmental agencies or nonprofit organizations, are included on the Federal Schedule. Direct and indirect costs are charged to awards in accordance with cost principles contained in the Uniform Guidance, U.S. Office of the Assistant Secretary Comptroller ("OASC"), OASC-3, A Guide for Hopsitals. Under these cost principles, certain types of expenditures are not allowable or are limited as to reimbursement. The accompanying Federal Schedule is presented on the accrual basis of accounting. Because the Federal Schedule presents only a selected portion of the activities of the Network, it is not intended to, and does not, present the consolidated financial position, results of operations, and changes in net assets or cash flows of the Network. While certain awards on the Federal Schedule have program names identified as award year 2021, 2022 and 2024 only expenses incurred during the year ended December 31, 2023 are reported on the Federal Schedule. These awards have grant periods that do not align with the Network's calendar year end. De Minimis Rate Used: N Rate Explanation: The Network charges indirect costs to federal awards based on award-specific rates as defined in each grant award. The Network is responsible only for the performance of certain administrative duties with respect to the Federal Direct Student Loan Program and, accordingly, the total outstanding loans are not included in the Network's consolidated financial statements. It is not practical to determine the balance of loans outstanding to students under this program as of December 31, 2023. The Federal Schedule includes loans granted in 2023.
Title: COVID-19 – Provider Relief Fund and American Rescue Plan (ARP) Rural Distribution Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the “Federal Schedule”) presents the activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. and its subsidiaries (the "Network") that have been financed by the U.S. Government. The information in this Federal Schedule is presented in accordance with the requirements of the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this Federal Schedule may differ from amounts presented in or used in preparation of the consolidated financial statements. All financial assistance received directly from federal agencies, as well as financial assistance passed through other governmental agencies or nonprofit organizations, are included on the Federal Schedule. Direct and indirect costs are charged to awards in accordance with cost principles contained in the Uniform Guidance, U.S. Office of the Assistant Secretary Comptroller ("OASC"), OASC-3, A Guide for Hopsitals. Under these cost principles, certain types of expenditures are not allowable or are limited as to reimbursement. The accompanying Federal Schedule is presented on the accrual basis of accounting. Because the Federal Schedule presents only a selected portion of the activities of the Network, it is not intended to, and does not, present the consolidated financial position, results of operations, and changes in net assets or cash flows of the Network. While certain awards on the Federal Schedule have program names identified as award year 2021, 2022 and 2024 only expenses incurred during the year ended December 31, 2023 are reported on the Federal Schedule. These awards have grant periods that do not align with the Network's calendar year end. De Minimis Rate Used: N Rate Explanation: The Network charges indirect costs to federal awards based on award-specific rates as defined in each grant award. The Federal Schedule includes grant activity related to the DHHS Coronavirus Aid Relief and Economic Security ("CARES") Act ALN 93.498 Provider Relief Funds ("PRF"). The PRF is administered by Health Resources and Services Administration ("HRSA"). As required based on guidance in the 2023 OMB Compiance Supplement, the Federal Schedule includes all Period 5 funds received between January 1, 2022 and June 30, 2022 and expended by June 30, 2023 as reported to HRSA via the PRF Reporting Portal. There were no period 6 funds received. The Federal Schedule, thus, includes $44,282 of lost revenue.
Title: COVID-19 – Federal Emergency Management Agency Disaster Relief Fund (“FEMA”) Accounting Policies: The accompanying Schedule of Expenditures of Federal Awards (the “Federal Schedule”) presents the activities of the federal financial assistance programs of Hackensack Meridian Health, Inc. and its subsidiaries (the "Network") that have been financed by the U.S. Government. The information in this Federal Schedule is presented in accordance with the requirements of the Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Therefore, some amounts presented in this Federal Schedule may differ from amounts presented in or used in preparation of the consolidated financial statements. All financial assistance received directly from federal agencies, as well as financial assistance passed through other governmental agencies or nonprofit organizations, are included on the Federal Schedule. Direct and indirect costs are charged to awards in accordance with cost principles contained in the Uniform Guidance, U.S. Office of the Assistant Secretary Comptroller ("OASC"), OASC-3, A Guide for Hopsitals. Under these cost principles, certain types of expenditures are not allowable or are limited as to reimbursement. The accompanying Federal Schedule is presented on the accrual basis of accounting. Because the Federal Schedule presents only a selected portion of the activities of the Network, it is not intended to, and does not, present the consolidated financial position, results of operations, and changes in net assets or cash flows of the Network. While certain awards on the Federal Schedule have program names identified as award year 2021, 2022 and 2024 only expenses incurred during the year ended December 31, 2023 are reported on the Federal Schedule. These awards have grant periods that do not align with the Network's calendar year end. De Minimis Rate Used: N Rate Explanation: The Network charges indirect costs to federal awards based on award-specific rates as defined in each grant award. As of December 31, 2023, the Network recorded $104,772 of claims to FEMA under ALN 97.036. The claims submitted represented incurred eligible capital and operating expenses attributed to the Network's response to COVID-19 which were not only expended but also obligated by the federal and state agencies. The Network has additional claims outstanding and under review with FEMA as of December 31, 2023 which will be recognized in the year the related funds are obligated by the federal and state agencies.